Atosiban is indicated to delay imminent pre-term birth in pregnant adult women with: - regular uterine contractions of at least 30 seconds duration at a rate of ≥ 4 per 30 minutes - a cervical dilation of 1 to 3 cm (0-3 for nulliparas) and effacement of ≥ 50% - a gestational age from 24 until 33 completed weeks - a normal foetal heart rate
Atosiban EVER Pharma is indicated to delay imminent pre-term birth in pregnant adult women with: − regular uterine contractions of at least 30 seconds duration at a rate of ≥ 4 per 30 minutes − a cervical dilation of 1 to 3 cm (0-3 for nulliparas) and effacement of ≥ 50% − a gestational age from 24 until 33 completed weeks − a normal foetal heart rate
Atosiban is indicated to delay imminent pre-term birth in pregnant adult women with: − regular uterine contractions of at least 30 seconds duration at a rate of ≥ 4 per 30 minutes − a cervical dilation of 1 to 3 cm (0-3 for nulliparas) and effacement of ≥ 50% − a gestational age from 24 until 33 completed weeks − a normal foetal heart rate
Atosiban accord injection is indicated to delay imminent pre-term birth in pregnant adult women with:- regular uterine contractions of at least 30 seconds duration at a rate of ≥ 4 per 30 minutes- a cervical dilation of 1 to 3 cm (0-3 for nulliparas) and effacement of ≥ 50%- a gestational age from 24 until 33 completed weeks- a normal foetal heart rate
Tractocile is indicated to delay imminent pre-term birth in pregnant adult women with: - regular uterine contractions of at least 30 seconds duration at a rate of ≥ 4 per 30 minutes - a cervical dilation of 1 to 3 cm (0-3 for nulliparas) and effacement of ≥ 50% - a gestational age from 24 until 33 completed weeks - a normal foetal heart rate
Tractocile is indicated to delay imminent pre-term birth in pregnant adult women with:− regular uterine contractions of at least 30 seconds duration at a rate of ≥ 4 per 30 minutes− a cervical dilation of 1 to 3 cm (0-3 for nulliparas) and effacement of ≥ 50%− a gestational age from 24 until 33 completed weeks− a normal foetal heart rate
Sun Pharmaceutical Industries Ltd.and Ranbaxy Laboratories Ltd have announced that they have entered into definitive agreements pursuant to which Sun...
Orexo AB (publ.), announces it has filed a patent infringement action in the United States District Court for the District of New Jersey, against Sun Pharmaceutical Industries Limited, Sun Pharma Global FZE, Sun Pharma Global, Inc., and Sun Pharmaceutical Industries, Inc.